missing translation for 'onlineSavingsMsg'
Learn More
Learn More
ER alpha/NR3A1 Antibody (h-151), Novus Biologicals™
Mouse Monoclonal Antibody
Brand: Novus Biologicals NB120-13538-0.05mg
This item is not returnable.
View return policy
Description
ER alpha/NR3A1 Monoclonal specifically detects ER alpha/NR3A1 in Human, Rat samples. It is validated for Western Blot, Immunocytochemistry/Immunofluorescence, Immunoprecipitation.
Specifications
| ER alpha/NR3A1 | |
| Monoclonal | |
| 1.0 mg/mL | |
| Western Blot 1:250, Immunocytochemistry/Immunofluorescence 1:10-1:2000, Immunoprecipitation 15 μg/mL | |
| P03372 | |
| ESR1 | |
| Synthetic peptide derived from the sequence of human Estrogen Receptor, conjugated to KLH | |
| 0.05 mg | |
| Cancer, Cell Biology, Cell Cycle and Replication, Dendritic Cell Markers, GPCR, Neuroscience, Signal Transduction, Transcription Factors and Regulators | |
| 2099 | |
| Human, Rat | |
| Purified |
| Immunofluorescence, Western Blot, Immunocytochemistry, Immunoprecipitation | |
| h-151 | |
| Unconjugated | |
| PBS (pH 7.2) and 50% Glycerol with 0.09% Sodium Azide | |
| ER, ER alpha, Era, ER-alpha, ESRESRA, Estradiol receptor, estrogen receptor, estrogen receptor 1, estrogen receptor alpha, estrogen receptor alpha delta 3*4,56,7*/819-2 isoform, estrogen receptor alpha delta 4 +49 isoform, estrogen receptor alpha delta 4*5,6,7*/654 isoform, NR3A1DKFZp686N23123, Nuclear receptor subfamily 3 group A member 1 | |
| Mouse | |
| Protein G purified | |
| RUO | |
| Primary | |
| Binding specificity was confirmed in peptide inhibition studies with the intact protein. This does not recognize the native estrogen receptor in the inactive 8S oligomeric state, but reacts efficiently with the activated 4S receptor. | |
| Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. | |
| IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction